| WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT–β-catenin–TCF signaling pathway M Katoh, H Kirikoshi, H Terasaki, K Shiokawa Biochemical and biophysical research communications 289 (5), 1093-1098, 2001 | 171 | 2001 |
| Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT-β-catenin-TCF signaling pathway H Terasaki, T Saitoh, K Shiokawa, M Katoh International journal of molecular medicine 9 (2), 107-112, 2002 | 166 | 2002 |
| The zebrafish-secreted matrix protein you/scube2 is implicated in long-range regulation of hedgehog signaling A Kawakami, Y Nojima, A Toyoda, M Takahoko, M Satoh, H Tanaka, ... Current Biology 15 (5), 480-488, 2005 | 125 | 2005 |
| FZD4S, a splicing variant of Frizzled-4, encodes a soluble-type positive regulator of the WNT signaling pathway N Sagara, H Kirikoshi, H Terasaki, Y Yasuhiko, G Toda, K Shiokawa, ... Biochemical and biophysical research communications 282 (3), 750-756, 2001 | 112 | 2001 |
| Human mesenchymal stem cells as a stable source of VEGF‐producing cells H Kagiwada, T Yashiki, A Ohshima, M Tadokoro, N Nagaya, H Ohgushi Journal of tissue engineering and regenerative medicine 2 (4), 184-189, 2008 | 107 | 2008 |
| EGF receptor kinase suppresses ciliogenesis through activation of USP8 deubiquitinase K Kasahara, H Aoki, T Kiyono, S Wang, H Kagiwada, M Yuge, T Tanaka, ... Nature communications 9 (1), 758, 2018 | 65 | 2018 |
| Functional importance of evolutionally conserved Tbx6 binding sites in the presomitic mesoderm-specific enhancer of Mesp2 Y Yasuhiko, S Kitajima, Y Takahashi, M Oginuma, H Kagiwada, J Kanno, ... Oxford University Press for The Company of Biologists Limited 135 (21), 3511 …, 2008 | 45 | 2008 |
| The mechanical properties of a cell, as determined by its actin cytoskeleton, are important for nanoneedle insertion into a living cell H Kagiwada, C Nakamura, T Kihara, H Kamiishi, K Kawano, N Nakamura, ... Cytoskeleton 67 (8), 496-503, 2010 | 43 | 2010 |
| IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer T Manabe, H Yasuda, H Terai, H Kagiwada, J Hamamoto, T Ebisudani, ... Molecular Cancer Research 18 (4), 549-559, 2020 | 39 | 2020 |
| Cullin-3–KCTD10-mediated CEP97 degradation promotes primary cilium formation T Nagai, S Mukoyama, H Kagiwada, N Goshima, K Mizuno Journal of cell science 131 (24), jcs219527, 2018 | 35 | 2018 |
| Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via … T Tomonari, Y Sato, H Tanaka, T Tanaka, Y Fujino, Y Mitsui, A Hirao, ... Oncotarget 11 (26), 2531, 2020 | 23 | 2020 |
| Transgenic analysis of the medaka mesp‐b enhancer in somitogenesis H Terasaki, R Murakami, Y Yasuhiko, T Shin‐i, Y Kohara, Y Saga, ... Development, growth & differentiation 48 (3), 153-168, 2006 | 19 | 2006 |
| Effect of gentamicin on growth and differentiation of human mesenchymal stem cells H Kagiwada, T Fukuchi, H Machida, K Yamashita, H Ohgushi Journal of toxicologic pathology 21 (1), 61-67, 2008 | 13 | 2008 |
| Assessing the activation/inhibition of tyrosine kinase‐related pathways with a newly developed platform H Kagiwada, T Kiboku, H Matsuo, M Kitazawa, K Fukui, K Horimoto Proteomics 21 (16), 2000251, 2021 | 4 | 2021 |
| Cyclo‐glycylproline attenuates hydrogen peroxide‐induced cellular damage mediated by the MDM2‐p53 pathway in human neural stem cells K Murotomi, H Kagiwada, K Hirano, S Yamamoto, N Numata, ... Journal of Cellular Physiology 238 (2), 434-446, 2023 | 2 | 2023 |
| Phosprof: pathway analysis database of drug response based on phosphorylation activity measurements H Kagiwada, C Motono, K Horimoto, K Fukui Database 2022, baac072, 2022 | 1 | 2022 |
| Analyzing device, analysis method program, and non-volatile storage medium K Horimoto, K Fukui, H Kagiwada US Patent App. 16/761,165, 2020 | 1 | 2020 |
| Nucleos (t) ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes R Shimizu, K Murai, K Tanaka, Y Sato, N Takeda, S Nakasyo, T Shirasaki, ... Hepatology Communications 8 (1), e0351, 2024 | | 2024 |
| Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment … Y Sato, T Tomonari, H Tanaka, T Tanaka, A Hirao, K Okamoto, ... Journal of Clinical Oncology 38 (4_suppl), 485-485, 2020 | | 2020 |
| Therapeutic Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma Beyond Progression with Sorafenib T Tomonari, Y Sato, H Tanaka, T Tanaka, Y Fujino, Y Mitsui, A Hirao, ... bioRxiv, 2020.01. 03.893800, 2020 | | 2020 |
